AVENTYL HYDROCHLORIDE
LOE ApproachingNDAORALCAPSULE
Approved
Nov 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Aventyl Hydrochloride is an oral capsule small-molecule antidepressant approved in 1964 by Eli Lilly. The generic name and mechanism of action data are unavailable, but the product represents a legacy tricyclic or related antidepressant class. Current indications and patient populations require verification from regulatory sources.
LOE Approaching
Competitive pressure at 30% signals moderate market erosion; small team likely focused on retention and cost-management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Aventyl represents a career in portfolio stewardship and lifecycle management rather than innovation or growth. Professionals should expect focus on cost-containment, access optimization, and competitive defense in a declining market.
Brand Manager (legacy portfolio management)Managed Care Specialist
Worked on AVENTYL HYDROCHLORIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.